Alzheimer's Disease TreatmentPRX005’s MTBR-targeting MOA is supported by recent data as a promising approach for Alzheimer’s disease treatment, reinforcing tau pathology modulation.
Drug DevelopmentPRX012 effectively impacts plaque clearance even at lower concentrations, with amyloid reduction being favorable while ARIA incidence remained consistent with placebo.
Therapeutic PotentialThe decision to investigate 200 mg and 400 mg doses in a once-monthly regimen reflects confidence in PRX012’s therapeutic potential.